Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Percheron Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
Health Check: Can Syntara produce the next multibillion-dollar Aussie blood cancer drug?
Health & Biotech
Scott Power: Which small medtech lifted 70pc this week after US contract win?
Health & Biotech
Health Check: No sign of frayed nerves as Orthocell girds for US approval
Health & Biotech
Health Check: Mayne Pharma and Acrux are on a drug expansion drive, generically speaking
Health & Biotech
Five ASX healthcare companies poised for game-changing catalysts
Health & Biotech
Health Check: Latest biotech quarterly results are as patchy as the curate’s egg
Health & Biotech
Dr Boreham’s Crucible: Does this biotech have the horsepower to become ‘the next Neuren’?
Health & Biotech
Health Check: ‘Cannabis corner’ in the green with record revenues and favourable deals
Health & Biotech
Health Check: Rats – and investors – are happy as Nyrada forges ahead with its first human trial
Health & Biotech
Scott Power: ASX health stocks rise as focus shifts to reporting season
Health & Biotech
Scott Power: Which health ‘underperformer’ just made a big move?
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall but there’s ‘wind in the sails again’
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall in ‘lacklustre’ week
Health & Biotech
Alive and Kicking: Noxopharm has difficult brain cancer in its sights
Health & Biotech
HealthInvest 2024 set to show off latest ASX healthcare innovators
Investor Guides
Investor Guide: Health & Biotech FY2025 featuring Tim Boreham
Health & Biotech
